The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions

• MAJOR ADVERSE CARDIAC EVENTS (MACE) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  

• Rates of procedural success [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
  
• Rates of Major Adverse Cardiac Event (MACE) [ Time Frame: In-hospital, 30 days, 6 and 24 months ] [ Designated as safety issue: Yes ]
  
• Rates of target lesion revascularization (TLR) [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
  
• Rates of stent thrombosis (acute, sub-acute, late and very-late) [ Time Frame: Up to 24 months follow-up ] [ Designated as safety issue: Yes ]
  

E-SERIES Registry is Prospective, multinational (Asia, South America and Europe), non-randomized, post-marketing web-based registry.

For this Study Up to 100 clinical sites in Asia, South America and Europe. Patients "ALL COMERS" assigned for percutaneous coronary interventions who present with at least one angiographically documented coronary artery lesion suitable for percutaneous treatment with the Supralimus® SES.

All subjects who provided signed informed consent prior to procedure, and have at least one lesion in a major epicardial vessel or major branch (>2.25mm), and are suitable for percutaneous treatment including stenting procedure with the Supralimus® SES. There are no limit regarding the number of lesions and/or study stents to be used, and stenting technique will be left at the operator's discretion; however, it is recommended according to the BEST interventional practice according to the current guidelines.

All patients will undergo follow-up clinical evaluation at 1, 6, 12 and 24 months. Angiographic follow-up will be performed at 6 months in a subset of high risk lesions including bifurcations (first 100 lesions) and left main stem (first 100 lesions).